Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Algernon Pharmaceuticals Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves 1 distinct examiner and 1 distinct art unit. This reflects a very narrow and specific focus for the company's current active patent filings. Such a concentrated profile allows for a highly specialized prosecution strategy, as the company only needs to address the specific requirements of a single examiner within a single art unit.
CAROLYN LOUISE LADD is the busiest examiner, overseeing the 1 busiest examiner pending action. Since there is only 1 pending office action in the portfolio, the company's immediate prosecution progress is entirely dependent on the resolution of this single matter. The concentration in 1 distinct art unit indicates a singular technical path for the current application. Practitioners should prioritize understanding this examiner's past decisions to improve the likelihood of a favorable outcome for the company's interests in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704395 | IFENPRODIL SALTS AND THERAPEUTIC USES THEREOF | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704395 | IFENPRODIL SALTS AND THERAPEUTIC USES THEREOF | LADD, CAROLYN LOUISE | 1622 | §103 | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial